Trial Profile
A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary) ; Sildenafil; Tadalafil
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms REPLACE
- Sponsors Bayer
- 13 Nov 2023 Results of pooled post hoc analysis (n=741 from studies PATENT-1, PATENT PLUS, RESPITE, MOTION, REPLACE) assessing the impact of riociguat in patients with PAH and comorbidities presented at the American Heart Association Scientific Sessions 2023
- 19 May 2021 Results of a subgroup analysis assessing the results of switching differed according to whether prior PDE5i treatment was given as monotherapy or in combination with an endothelin receptor antagonist presented at the 117th International Conference of the American Thoracic Society
- 28 Apr 2021 Results from of risk analysis assessment, presented at the 41st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.